U.S. markets close in 2 hours 12 minutes
  • S&P 500

    4,156.13
    -32.30 (-0.77%)
     
  • Dow 30

    34,303.43
    -439.39 (-1.26%)
     
  • Nasdaq

    13,409.00
    +7.15 (+0.05%)
     
  • Russell 2000

    2,207.14
    -5.56 (-0.25%)
     
  • Crude Oil

    65.41
    +0.49 (+0.75%)
     
  • Gold

    1,835.00
    -2.60 (-0.14%)
     
  • Silver

    27.66
    +0.16 (+0.59%)
     
  • EUR/USD

    1.2162
    +0.0028 (+0.23%)
     
  • 10-Yr Bond

    1.6240
    +0.0220 (+1.37%)
     
  • GBP/USD

    1.4156
    +0.0035 (+0.25%)
     
  • USD/JPY

    108.6300
    -0.2110 (-0.19%)
     
  • BTC-USD

    56,319.60
    -1,170.38 (-2.04%)
     
  • CMC Crypto 200

    1,504.47
    +1,261.79 (+519.94%)
     
  • FTSE 100

    6,947.99
    -175.69 (-2.47%)
     
  • Nikkei 225

    28,608.59
    -909.71 (-3.08%)
     

ChemoCentryx to Hold First Quarter 2021 Financial Results Conference Call on Thursday, April 29, 2021

  • Oops!
    Something went wrong.
    Please try again later.
ChemoCentryx, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

MOUNTAIN VIEW, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2021 financial results will be released after market close on Thursday, April 29, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on April 29, 2021 to discuss these results and to answer questions.

To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 3963565. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 Glomerulopathy (C3G).

ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:

Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
investor@chemocentryx.com

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
Lee Roth, Burns McClellan
212.213.0006
lroth@burnsmc.com